News

1 to 9 of 10 results

Bladder cancer market to witness moderate growth by 2017, despite anticipated launch of EOoquin

Bladder cancer market to witness moderate growth by 2017, despite anticipated launch of EOoquin

22-01-2014

The bladder cancer therapeutics market in the six major countries is forecast to climb from $239.3 million…

EOquinEuropeMarkets & MarketingOncologyPharmaceuticalSpectrum PharmaceuticalsUSA

Ligand to earn up to $50 million in deal with Spectrum for Captisol-enabled melphalan

14-03-2013

Ligand Pharmaceuticals (Nasdaq: LGND) has signed a global license and supply agreements with fellow US…

FinancialLicensingLigand PharmaceuticalsmelphalanOncologyPharmaceuticalSpectrum Pharmaceuticals

Global epigenetic therapies market to increase at a CAGR of 10% through 2017

04-03-2013

The global epigenetic therapies market is expected to reach a total value of around $2.518 billion by…

belinostatBiotechnologyCelgeneFaridakGlobalMarkets & MarketingNovartisOncologypanobinostatPharmaceuticalSpectrum PharmaceuticalsTopotargetVidaza

Topotarget says belinostat pivotal trial meets primary endpoint

26-09-2012

Denmark's Topotarget (Nasdaq OMX: TOPO) said that the primary endpoint has been met for the pivotal trial…

belinostatOncologyPharmaceuticalResearchSpectrum PharmaceuticalsTopotarget

Spectrum plunges on negative trial results; makes bid for Allos

10-04-2012

US biotech firm Spectrum Pharmaceuticals (Nasdaq: SPPI) saw its shares plunge as much as 14%, before…

Allos TherapeuticsapaziquoneBiotechnologyFolotynMergers & AcquisitionsOncologyPharmaceuticalResearchSpectrum Pharmaceuticals

Spectrum in-licenses novel GCSF drug from Hanmi Pharma

01-02-2012

USA-based Spectrum Pharmaceuticals (NasdaqGS: SPPI) has entered into a co-development and commercialization…

Hanmi PharmaceuticalLicensingOncologyPharmaceuticalSpectrum Pharmaceuticals

Spectrum Pharma to acquire non-US rights to market Zevalin

26-01-2012

USA-based Spectrum Pharmaceuticals (NasdaqGS: SPPI) says it has entered into an agreement to acquire…

BayerMergers & AcquisitionsOncologyPharmaceuticalSpectrum PharmaceuticalsZevalin

US FDA approves J&J’s Zytiga for late-stage prostate cancer and Spectrum’s Fusilev for metastatic colorectal cancer

03-05-2011

Ahead of the holiday weekend, the US Food and Drug Administration announced a couple of new drug approvals:…

BiotechnologyFusilevJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationSpectrum PharmaceuticalsZytiga

1 to 9 of 10 results

COMPANY SPOTLIGHT

Menarini

Back to top